MRI and MRS in HMG-CoA lyase deficiency

3-Hydroxy-3-Methylglutaryl coenzyme A lyase (HMG-CoA) deficiency is a rare inborn error of leucine catabolism. The disease is characterized by recurrent episodes of metabolic acidosis, hyperammonemia without ketosis, hypoglycemia, lethargy, hepatomegaly, and seizures. This study has evaluated the magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) findings of three patients with HMG-CoA deficiency. The common findings on all of the MRI scans were multiple, coalescent, marked lesions in periventricular white matter and arcuate fibers, most prominently in frontal or periatrial regions that were superimposed on diffuse, slightly hyperintense subcortical white matter signal. Involvement of the caudate nucleus and the dentate nucleus were observed in the reported patients. MRS studies by both STEAM and PRESS spectra of all patients revealed a decrease in N-acetylaspartate and elevation in both myoinositol and choline. A pathologic peak at 1.33 ppm, which is compatible with lactate, and a particular peak at 2.42 ppm in all patients were also found. The combination of both MRI and MRS findings could be considered as being specific in patients with HMG-CoA lyase deficiency.     

膀胱移行细胞癌微卫星不稳定性及其机制的研究

目的　探讨膀胱移行细胞癌 (BTCC)染色体微卫星不稳定性的表现及与基因突变的关系。方法　采用聚合酶链反应 (PCR)方法检测 4 0例 BTCC患者 5个微卫星位点的改变 ,同时用同样的方法检测癌组织中BAX基因和转化生长因子 (TGF) - β 型受体基因移码突变的情况。结果　至少发生一个微卫星位点改变的阳性率为 82 % (33/ 4 0 ) ,D9S16 2、D16 S4 76、D9S5 4、FGA和干扰素 (IFN) - A1位点改变各自的阳性率分别为 5 8%(2 3/ 4 0 )、 4 2 % (17/ 4 0 )、 38% (15 / 4 0 )、 4 8% (19/ 4 0 )和 5 5 % (2 2 / 4 0 ) ,阳性检出率与良性病变差异有显著性 ,与肿瘤的分期分级无显著相关性。发生微卫星改变的 33例中 ,33% (11/ 33)和 4 2 % (14 / 33)分别可见 TGF- β 型受体基因和 BAX基因的移码突变。结论　检测染色体微卫星的改变是 BTCC早期诊断、监测复发的有效手段 ,染色体微卫星改变可能是 BTCC发生过程中多基因突变的一种表现形式     

软式膀胱尿道镜检查技巧

目的 :提高软式膀胱尿道镜检查的技术水平。方法 :报告软式膀胱尿道镜检查的成功经验及所遇问题。结果 :软式膀胱尿道镜对膀胱、尿道的观察均具有明显的优势 ,可完成活检、插管、取异物等多项操作。结论 :软式膀胱尿道镜检查痛苦小 ,可替代硬式膀胱尿道镜 ,使用广泛 ;熟练掌握软式膀胱尿道镜的操作技巧是检查成功及延长使用寿命的关键     

Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine

OBJECTIVE: The present study was carried out to evaluate the safety and immunogenicity of the Haemophilus influenzae type b-CRM197 (Hib-CRM197) conjugate vaccine in relation to the change of adjuvant from aluminum hydroxide to aluminum phosphate (AlPO4). METHODS: The present study was a clinical phase II, observer-blind, randomized, multicenter, controlled study. Subjects were healthy infants aged 6-12 weeks, eligible for expanded program of immunization (EPI) routine vaccination and admitted to Hacettepe University Department of Social Pediatrics and Gülveren Health Center, Ankara. A total of 520 healthy infants were randomized in a 2:2:1 ratio to receive at either Chiron Hib/AlPO4 vaccine or VaxemHib (aluminum hydroxide adjuvant) vaccine or HibTiter (no adjuvant). Vaccines were administered simultaneously with routine diphtheria, tetanus and pertussis (DTaP) and oral polio vaccine (OPV) vaccines at 2, 4 and 6 months of age. Blood samples for anti-plain polysaccharide (PRP) antibody measurement were collected before the first vaccination and 1 month after the last vaccination. After each vaccination parents filled out a diary for 7 days. RESULTS: Out of 520 subjects enrolled, 514 received three doses and were included for safety analysis. Local and systemic reactions occurred with low and similar frequencies in all groups. Only erythema was more common in Chiron Hib/AlPO4 vaccine (19, 10, 11% in Chiron Hib/AlPO4, VaxemHib and HibTiter, respectively, P < 0.05). Nine serious adverse events were reported in seven cases of which none were related to vaccines. A total of 504 subjects were included in the immunogenicity analysis. The three vaccines were highly immunogenic and equivalent in terms of percentage of acquisition of long-term protective levels. The anti-PRP geometric mean titers were 9.9, 8.3 and 5.14 micro g/mL, respectively (P < 0.05). CONCLUSIONS: The use of aluminum compounds adjuvants in Hib-CRM197 conjugate vaccines does not impact the safety profile, while it does increase the magnitude of anti-PRP antibody titers.     

The best management of superficial bladder tumours: Comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?

To compare retrospectively the recurrence rates of TUR alone versus different intravesical chemotherapy modalities in superficial bladder cancer cases, 187 patients with stage Ta and T₁ bladder tumours were treated with transurethral resection followed by adjuvant intravesical chemotherapy with mitomycin, BCG or epirubicin or by transurethral resection alone. All patients in this study had historically proven transurethrally resectable primary, category Ta and T₁ transitional cell carcinoma (TCC) of the bladder. Group I included transurethral resection alone, and the other groups included intravesical mitomycin-C(Group II), BCG (Group III) and epirubicin (Group IV) therapies after transurethral resection. 146 male and 41 female patients (78% male and 22% female patients) in this study were diagnosed as primary TCC bladder tumours. Only 52 of them were stage Ta and 135 of them were stage T₁ bladder tumours. Examining the histological grade of the bladder tumours, 88 (47%) of the patients had grade I, 53 (28%) had grade IIa, 30 (16%) had grade IIb and remaining 16 (9%) had grade III bladder cancers. The recurrence rates were 25% for Group I, 23.8% for Group II, 26.2% for Group III and 22.7% for Group IV. These values were given with disregarding the grade and volume of the bladder tumours. For solitary, less than 3 cm low grade tumours (grade I, IIa) recurrence rates were 16% for Group I, 15.4% for Group II, 17.8% for Group III, 17.2% for Group IV (p> 0.05). As a result of this retrospective study, for patients with low grade, stage Ta and T₁ tumours TUR alone may be the best treatment modality. Although intravesical chemotherapy is effective in decreasing short-term incidences of tumour recurrence, it has not decreased long-term incidences of tumour recurrence. The high cost and adverse side effects of intravesical chemotherapy should also be taken into consideration in superficial, single, low grade tumours of bladder. This revised version was published online in August 2006 with corrections to the Cover Date.     

异丙酚对神经元缺氧损伤的保护及其作用机制

目的　研究异丙酚对离体大鼠海马神经元缺氧损伤的保护作用及其机制。方法　以原代培养的大鼠海马神经元作为研究对象 ,建立缺氧、H2 O2 和谷氨酸损伤模型 ,用MTT法测定神经元存活率。采用激光扫描共聚焦显微镜动态监测缺氧前后 ,单个海马神经元内Ca2 + 浓度和线粒体膜电位 (△Ψm)的变化。用电子自旋共振技术测定异丙酚对羟基自由基和超氧阴离子自由基的清除作用。结果　 6～ 4 8mg·L-1浓度的异丙酚可明显降低神经元缺氧损伤时的细胞死亡率 (P <0 0 1) ,作用程度均呈剂量相关 (r =0 89,P <0 0 5 ) ;2 4～ 4 8mg·L-1浓度的异丙酚可明显降低H2 O2 损伤时的细胞死亡率 (P <0 0 1) ;12～ 4 8mg·L-1浓度的异丙酚可明显降低谷氨酸损伤时的细胞死亡率 (P <0 0 1)。 3～ 4 8mg·L-1异丙酚对缺氧诱发的细胞内钙离子超载有抑制作用(P <0 0 5 ) ;12、4 8mg·L-1异丙酚能减缓缺氧引起的△Ψm降低 (P <0 0 1)。 12、4 8mg·L-1异丙酚对羟基自由基的清除率分别为 17 1%和 2 1 1% ,但对超氧阴离子自由基无清除作用。结论　异丙酚对离体培养的大鼠海马神经元缺氧性损伤具有保护作用 ,其作用机制部分与异丙酚抑制缺氧引起的 [Ca2 + ]i 异常升高、抑制线粒体膜电位的下降和清除羟基自由基有关     

丙泊酚对N-甲基-D-天冬氨酸所致PC12细胞损伤的保护作用

目的　探讨静脉麻醉药丙泊酚 (PPF)脑保护作用的可能机制。方法　乳酸脱氢酶 (LDH)法及MTT比色法判断细胞损伤程度及细胞存活率 ,Fura 2 /AM荧光标记法测定细胞内Ca2 + 浓度 ( [Ca2 + ]i)的变化 ,分光光度法测定细胞一氧化氮合酶 (NOS)活性。结果　N 甲基 D 天冬氨酸 (NMDA) 3 0 0 μmol·L-1处理4h可明显导致PC1 2细胞的损伤 ,表现为LDH释放量明显增加 ,吸光度值A570nm明显降低 ,细胞存活率降低 ,同时 [Ca2 + ]i 和NOS活性则明显增加。PPF6.2 5 ,2 5 ,1 0 0 ,40 0 μmol·L-1与NMDA同时处理PC1 2细胞则使LDH释放量显著降低 ,细胞存活率增加。PPF 1 2 .5和 1 2 5 μmol·L-1可显著降低NMDA诱导的[Ca2 + ]i 水平及NOS活性的提高。结论　PPF对NMDA所致的PC1 2细胞损伤有明显的保护作用 ,其机制可能与其抑制NMDA受体的功能 ,降低 [Ca2 + ]i,减弱Ca2 + 超载 ,并降低NMDA诱导的NOS活性增加有关。提示PPF可能是通过抑制NMDA受体 Ca2 + NOS通路的功能而产生细胞保护效应     

白术对抗体形成细胞的作用研究

目的：观察白术对小鼠抗体形成细胞的作用。方法：用100％浓度白术浸出液定期给小鼠灌胃，然后检测小鼠抗体产生能力．特异玫瑰花环结形成细胞检测(SRFC)、血清IgG检测。结果：用药组以上三项免疫学指标均增高，结论：白术有明显促进抗体形成细胞的作用。     

视黄酸依赖反义cyclin D1对HL-60细胞增殖和分化的影响及其机制

目的 :探讨视黄酸 (retinoicacid ,RA)及其诱导的反义 (anti sense ,AS)cyclinD1对肿瘤细胞的协同抑制增殖与诱导分化效应及其机制。方法 :通过构建的含有视黄酸反应元件 (retinoicacidresponseelement ,RARE)的反义cyclinD1RNA表达载体 pCI neo/RARE3 TK/AscyclinD1,使反义cyclinD1的表达可受RA诱导调控。以脂质体转染HL 60白血病细胞后 ,运用生长曲线、MTT比色法和流式细胞仪分析检测细胞增殖功能 ,NBT还原实验和透射电镜观测细胞分化状况 ,western blot检测p16基因蛋白表达水平。结果 :反义cy clinD1转染和未转染的HL 60细胞经RA处理后 ,生长减慢 ,细胞被阻滞在G0 /G1期 ,分化能力明显增强 ,p16基因蛋白表达增加 ,其中 ,以反义cyclinD1转染细胞经RA处理后变化更为明显。结论 :RA及其诱导的反义cyclinD1可协同抑制HL 60细胞增殖和诱导细胞分化成熟 ,上调p16基因表达可能是其分子机制之一。